A166

DRUG4 trials

Sponsors

Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Conditions

Bile Duct CancerBladder CancerBreast CancerBreast Neoplasm Malignant PrimaryCervical CancerCholangiocarcinomaColo-rectal CancerHER-2 Gene Amplification

Phase 1

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

CompletedNCT03602079

Klus Pharma Inc.Bile Duct Cancer, Bladder Cancer, Breast Neoplasm Malignant Primary +41

Start: 2018-07-16End: 2022-01-12Updated: 2023-08-03

A Study of A166 in Patients With Advanced Solid Malignant Tumors

Active, not recruitingNCT05311397

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Breast Cancer

Start: 2018-08-09End: 2026-12-31Target: 120Updated: 2026-05-08

Phase 2

A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

RecruitingNCT07299825

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Her 2 Positive Breast Cancer

Start: 2024-09-20End: 2027-12-31Target: 40Updated: 2026-05-08

Phase 3

A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy

Active, not recruitingNCT06968585

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.HER2-positive Breast Cancer

Start: 2023-07-18End: 2028-03-31Updated: 2026-05-08

Related Papers

Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial.

2026-09-11

Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine.

2020-08-0632 citations

A first in-human study of A166 in patients with locally advanced/metastatic solid tumors which are HER2-positive or HER2-amplified who did not respond or stopped responding to approved therapies.

Journal of Clinical Oncology2020-05-2048 citations